FDA Plays

[colorofmoney]

Color of Money Green Pick of the Day-Aethlon Medical Establishes Exosome Sciences, Inc.

* Press Release
* Source: Aethlon Medical, Inc.
* On 10:30 am EDT, Thursday October 22, 2009

Companies:
o Aethlon Medical Inc.

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD - News) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company. ESI will seek to leverage the recent discovery that the Hemopurifier®, a medical device developed by Aethlon Medical as a broad-spectrum therapy against infectious viral pathogens, is effective in capturing exosomes that are secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. Aethlon Medical, Inc. will contribute into ESI all exosome-related patents and patents pending.
Related Quotes
Symbol Price Change
AEMD.OB 0.47 +0.15
Chart for AETHLON MEDICAL INC
{"s" : "aemd.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

Jim Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc. said, "The ability to reduce circulating exosomes would likely reverse immune suppression and increase patient responsiveness to both immunotherapy and chemotherapy, thus positioning ESI to participate in the $43 billion cancer therapy market. ESI also plans to advance exosome diagnostic and research services, and explore recently discovered opportunities to address exosomes in disease conditions beyond cancer."

In the last year alone, an increasing number of research driven science publications reveal that exosomes have implications in inflammatory conditions including Sepsis, bacterial infections including Tuberculosis (TB), autoimmune conditions such as Rheumatoid Arthritis, and neurological and neurodegenerative diseases such as Alzheimer's disease The growth in the exosome industry is further evidenced by published research and citations increasing from 140 articles in 2001 to 1,160 articles and citations in 2008.

"ESI allows us to leverage the previously unrecognized value of our non-infectious disease research into a new asset that positions us to be an important participant in the emerging exosome industry. We also maintain the option of installing an independent management team at ESI and if appropriate in the future, may spin out part or all of ESI as a means to achieve fuller valuation for Aethlon Medical shareholders," concluded Joyce.

A recent publication entitled, "Exosomes as a Tumor Immune Escape Mechanism: Possible Therapeutic Implications" discusses the potential for the Hemopurifier® to become the first therapeutic strategy to inhibit the immune suppression caused by tumor secreted exosomes. The abstract and complete article is available to be accessed online at: www.translational-medicine.com/content/6/1/37.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:

RedChip Companies, Inc.
Jon Cunningham
1-800-733-2447, Ext. 107
[e-mail]

Jim Joyce
Chairman, CEO
858.459.7800 x301
[e-mail]

Jim Frakes
Senior VP Finance
858.459.7800 x300
[e-mail]

Buzz up! 3
Send
Share
Print
Share this page

*
Delicious
*
Twitter
*
Myspace
*
Digg
*
StumbleUpon
*
Facebook

Related Headlines

* Aethlon Medical Establishes Exosome Sciences, Inc. - PR Newswire
* Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus - PR Newswire
* Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference - PR Newswire
* CEO Interviews and Company Presentation Videos From RedChip's 2009 New York Equities Conference Now Available Online - GlobeNewswire
* Aethlon Medical Announces BIOCOM Conference Presentation - PR Newswire

Always do your own DD!